Navigation Links
Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
Date:4/12/2011

ic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Novartis has submitted marketing applications for everolimus for this use to the European Medicines Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and additional regulatory submissions are under way worldwide.

Afinitor is available in the US in 2.5 mg, 5 mg and 10 mg tablet strengths. With once-daily dosing, Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.

In the US, everolimus is available in different dosage strengths for the non-oncology patient population under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. As an investigational compound the safety and efficacy profile of everolimus has not yet been established in pancreatic or any other type of NET. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for pancreatic or any other type of NET or any additional indications anywhere in the world.

Important Safety Information for Afini
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
2. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
3. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
4. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
9. Novartis to Expand Global Research Headquarters in Cambridge, MA
10. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
11. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- The North American spine surgery devices market is ... U.S. having the maximum market share. This region is ... The market, by product type, encompasses spinal ... devices, non-fusion implant devices, and spine bone stimulators devices. ... is the largest and fastest-growing segment. Key players ...
(Date:6/3/2015)...  Actavis plc (NYSE: ACT ), a leading global ... and President of Actavis, will provide an overview and update ... Global Healthcare Conference in Rancho Palos Verdes, Calif. ... The presentation will take place on Wednesday, June ... Resort, Rancho Palos Verdes, Calif.  To ...
(Date:6/3/2015)... , June 02, 2015 Research ... addition of the "The Future of Pharmaceutical ... As they are in a desperate need to ... low cost, drug companies have been increasingly utilizing ... their productivity while constantly streamlining their internal operation. ...
Breaking Medicine Technology:Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MOUNTAIN VIEW, Calif. , Jan. 28 Omnicell, Inc. (Nasdaq: ... facilities, today announced results for its fourth quarter and year ended ... fourth quarter of 2009 was $54.7 million , up $0.7 ... $7.4 million or 11.9% from the fourth quarter of 2008. ...
... , SAN DIEGO , Jan. 28 ... Phase II clinical trial evaluating CTS-1027 in combination with pegylated ... activity, safety and tolerability of the triple combination will be ... is a significant unmet medical need in HCV patients who ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:6/3/2015)... Accountable care organizations (ACOs) are increasingly partnering ... worries that these product types were too similar to ... that product-based ACOs will continue to grow in size ... June issue of Atlantic Information Services, Inc.’s (AIS) AIS’s ... that the backlash from HMOs seems to be fading ...
(Date:6/3/2015)... Save On Medical ( http://www.saveonmedical.com ) ... shopping for health care procedures easier for patients on ... look and makes it easier to compare the prices ... , Now, when patients search for the procedure they ... they can see the provider’s price and Docometer quality ...
(Date:6/3/2015)... The National Resident Matching Program Board of Directors ... of Medical Education at the University of California, San Diego ... , “It is an honor to assume the ... Dr. Savoia. “NRMP’s goal is to provide a fair, ... programs, and I welcome the opportunity to guide the organization ...
(Date:6/3/2015)... 2015 Dr. Steven Reisman, a nationally recognized ... ( http://www.newyorkcardiac.com ) located in NYC, announced today the expansion ... practice. In most cases, depending on the level of care ... call, they will be seen by a cardiologist that same ... cardiologist is to ensure that people who have an urgent ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 A ... will be honored with a Global Inspire Award at ... recognizes the organization’s outstanding volunteers for their leadership, level ... scale. , The recipients of the Author(s) ... group of authors whose article has made a significant ...
Breaking Medicine News(10 mins):Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 3Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4
... as eunuchs, can now choose a gender of their liking ... //to a special procedure developed at the All India Institute ... 1,100 patients have already given proper gender identities as males ... life, doctors at the premier research and referral institute said. ...
... looking at lactate with a much more positive eye, ... in the immediate //hours after a traumatic brain injury ... right, it could change how emergency room physicians and ... the first critical hours after injury. ,Previous ...
... technology that can quickly screen all 20,000-plus human genes for ... affect how sensitive human cancer cells are to certain chemotherapy ... in the April 12 edition of the journal Nature, researchers ... library of small RNA molecules – the first used by ...
... With allergy season in full bloom, the American Academy of ... of what you can do to cope with the pollen ... specialist can help. // ,This spring, pollen from blooming ... 45 million Americans, causing itching eyes, sneezing, nasal stuffiness, nasal ...
... in erectile dysfunction, decreased libido, anemia, sarcopenia, memory loss, ... ,While a low serum testosterone level is well-known for ... overall physical functioning and fall risk has not been ... of the Archives of Internal Medicine, Orwoll and colleagues ...
... of Queensland men have never been screened for prostate, colorectal ... ,Screening for colorectal cancer currently has stronger scientific evidence for ... skin cancer, but a new study in the Medical Journal ... colorectal cancer test than the other two. ...
Cached Medicine News:Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2Health News:Gene Screening Points Way to More Effective Chemotherapy 2Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2Health News:Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men 2
... IgG Test is an ELISA ... of IgG to Varicella Zoster ... used as,an aid to determine ... status may be determined using ...
The ImmunoWELL Thyroglobulin IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroglobulin in serum and is used as an aid ...
... Screening Panel 4 is an enzyme ... detection of autoantibodies against various specific ... and Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Medicine Products: